Catalent, Inc. announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer. Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring. In addition, Catalent has promoted Mike Riley to Region President, Biologics North America, and appointed Manja Boerman as Region President, Biologics Europe, where each will lead all development, manufacturing, and commercial activity in their respective regions, as well as growing Catalent Biologics’ business. Mr. Riley has been with Catalent for nearly 15 years and previously served as Vice President/General Manager of Catalent Biologics. In his new role, Mr. Riley will oversee the sites in Bloomington and Madison, as well as Emeryville, California, and the company’s Biologics operations at its facilities in Research Triangle Park, North Carolina, and Kansas City, Missouri. Ms. Boerman joined Catalent in December 2019 from her previous role as President of Aesica Pharmaceuticals, and has over 20 years’ experience in biotech and pharmaceutical services. She will oversee the company’s European biologics sites, including Brussels, Belgium and its newly acquired site in Anagni, Italy, which is a facility for late-phase tech transfers and commercial product launches. Both Ms. Boerman and Mr. Riley have also joined Catalent’s Executive Leadership Team and report directly to Ms. Flynn. Pete Buzy will continue to lead Catalent’s Gene Therapy business, where, under his guidance, Catalent has been investing significantly in capacity, equipment, and expertise needed to meet strong and growing demand for custom development and manufacturing of adeno-associated virus (AAV) vectors, next-generation vaccines, and oncolytic viruses. Ms. Flynn has over 30 years’ experience in commercial, operations, and general management roles within the pharmaceutical services industry, and she rejoins Catalent after more than 11 years, having previously spent eight years as part of Cardinal Health/Catalent in various commercially focused roles. Her most recent position was Senior VP and Chief Commercial Officer for West Pharmaceutical Services.